Experiment 374159

Compounds isolated

Details

PropertyValue
Pharmacology
Administration routeORAL
OrganismEmpty organism
CitationKARLSSON,MO: DAHLSTROM,B: ECKERNAS,SA: JOHANSSON,M: ALM,AT:. (1990). PHARMACOKINETICS OF ORAL NOSCAPINE.. 1990(39)
Amount utilized
Compound isolated
DiseaseTHE RELATIVE BIOAVAILABILITY IN 20 HEALTHY VOLUNTEERS OF 100 MG, 200 MG AND 300 MG TABLETS OF NOSCAPINE AND 200 MG AS A SOLUTION HAS BEEN ASSESSED IN A FOUR-WAY CROSS-OVER STUDY, WITH REPEATED ADMINISTRATION OF THE 200 MG DOSE TO ASSESS INTRAINDIVIDUAL VARIABILITY. THERE WAS A DISPROPORTIONATE INCREASE IN THE AUC OF NOSCAPINE TABLETS, AS A 3-FOLD INCREASE IN DOSE PRODUCED A 9-FOLD RISE IN AUC. THIS DOSE-DEPENDENCY COULD MAINLY BE ATTRIBULTED TO SATURABLE FIRST-PASS METABOLISM OF THE DRUG. ADMINISTRATION OF NOSCAPINE AS A SOLUTION RESULTED IN A SIGNIFICANTLY HIGHER MAXIMAL CONCENTRATION AT AN EARLIER TIME-POINT AND A HIGHER AUC THAN THE CORRESPONDING DOSE AS TABLETS. REPEATED ADMINISTRATION OF NOSCAPINE TABLETS AND SOLUTION YIELDED HIGHER AUC ON THE SECOND DOSING OCCASION. NO CAUSE FOR THIS CARRY-OVER EFFECT WAS FOUND, AND THE CONTRIBUTION OF REMAINING NOSCAPINE WAS NEGLIGIBLE. THE TERMINAL HALF-LIFE OF NOSCAPINE, WHICH WAS INDEPENDENT OF FORMULATION OR DOSE SIZE WAS 4.5 H. BOTH INTER-AND INTRAINDIVIDUAL VARIABILITY IN NOSCAPINE KINETICS WERE VERY HIGH, E.G. 73% AND 51% CV OF THE AUC FOR THE 200 MG TABLET.
Dose amount200.0 MG
Number1
Qualitative resultACTIVE
AnimalHUMAN ADULT
Dose expressionDOSE
GenderMALE